Freehold, NJ -- May 4, 2016 -- InvestorsHub NewsWire -- MEDIFIRST SOLUTIONS, INC. (OTCQB: MFST) (the “company” or “Medifirst”) would like to update shareholders on the most recent developments regarding its FDA 510(k) submission for The Time Machine Laser Series.

As recently announced, The Time Machine Laser Series engineers have upgraded the lasers for better durability and have made several internal modifications as requested as part of the FDA review process. Medifirst is pleased to announce that it has completed the safety testing evaluation and has successfully passed the lab tests for the updated modifications to the upgraded Time Machine Laser. Commented CEO Bruce J. Schoengood, “ We are excited and pleased that the laser safety data for the upgraded modifications meets the AAMI ES60601-1 standards.”

Continued CEO Bruce J. Schoengood, “ As requested by the lab that’s conducting the Time Machine Laser tests and evaluation, Medifirst is making text and information updates to the laser manual including final data sheets, additional documentation and completing all final print materials. Upon successfully completing and passing the last remaining lab tests, we will begin preparing our response to the FDA and we anticipate completion of the submission before the June deadline. The company would like to thank all  its shareholders for their support and will continue to announce updates on a regular basis.”

About Medifirst Solutions, Inc.
Medifirst Solutions, Inc. is a Nevada corporation that is headquartered in New Jersey. The company seeks innovative medical and healthcare products and technologies which are targeted to both medical and healthcare professionals, as well as everyday consumers. Medifirst is developing and establishing both consumer and professional medical cliental that can serve as a pipeline that will allow for distribution of future products and services. For more details visit www.medifirstsolutions.com for more information.

About the Lasers
Medical Lasers Manufacturer, Inc., a Nevada company, (“MLM”), a Medifirst subsidiary, will specialize in producing high quality hand-held mobile lasers. The laser division, including products and treatment programs, will be operated out of MLM. The company’s focus is to help patients with specific cosmetic skin conditions, as well as relief of muscle and joint pain and muscle spasm and inflammation. Driven by the huge demand for minimally invasive skin and pain treatments, the global market for medical and therapeutic lasers have been estimated to grow as high as to $4 billion in 2015.


Forward-Looking Statements:  The statements in this press release that relate to the company's expectations with regard to the future impact on the company's results from new products in development are forward-looking statements, and may involve risks and uncertainties, some of which are beyond our control.  Such risks and uncertainties are described in greater detail in our filings with the U.S. Securities and Exchange Commission.  Since the information in this press release may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.  We make no commitment to disclose any subsequent revisions to forward-looking statements.
 
Contact:    Investor Relations
Phone:      732) 786-8044
Email:        info@medifirstsolutions.com
Website:    www.medifirstsolutions.com